Considering China For Clinical Studies The Pharma and Biotech Perspective
Sponsored by:
Almost 50% of biopharma are con-sidering China for clinical studies because of vast patient pools, competitive approval pathways, and cost savings.
Keep up with the top pharma business news of the week. On the go.
Sponsored by: